XELJANZ in Psoriatic Arthritis; A Curious Case History
Please sign in or register to view this video
In this video, Dr Richard Smith presents a patient case study to discuss his experience prescribing XELJANZ in PsA.
Xeljanz▼ (tofacitinib citrate) Prescribing Information
Enbrel® (etanercept) Prescribing Information
Inflectra™(infliximab) Summary of Product Characteristics | Legal Category: POM Basic NHS Price: 1 vial £377.66
Ruxience®▼ (rituximab) Summary of Product Characteristics | Legal Category: POM Basic NHS Price: 100mg 1 vial £157.17, 500mg 1 vial £785.84
Dr Richard Smith is a Consultant in Rheumatology, Musculoskeletal and Sports Medicine practicing at Salisbury NHS Foundation Trust and New Hall Hospital, Bodenham. He is also a visiting Rheumatologist to King Edwards Memorial Hospital, Port Stanley in the Falklands Islands. He trained at St Mary's Hospital, London and completed his diploma in Sports and Exercise Medicine at the University of Bath. Dr Smith offers a range of clinical expertise in Arthritis, Osteoporosis, Gout, Back Pain, Upper and Lower Limb Disorders and Sports Medicine. He is a member of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis). In this video Dr Smith discusses a case of an adult patient diagnosed with psoriatic arthritis
PP-XEL-GBR-2593. January 2021
XELJANZ Risk Minimisation Programme (RMP) materials, including a Patient Alert Card, Prescriber Checklists and a Prescriber Brochure are available from https://www.medicines.org.uk/emc/. Patients treated with XELJANZ should be given the Patient Alert Card.